Search

Your search keyword '"Nian, Weiqi"' showing total 130 results
Start Over Author "Nian, Weiqi"
130 results on '"Nian, Weiqi"'

2. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutationsSunvozertinib for NSCLC with EGFR Exon20ins

Author

Wang, Mengzhao, Yang, James Chih-Hsin, Mitchell, Paul L, Fang, Jian, Camidge, D Ross, Nian, Weiqi, Chiu, Chao-Hua, Zhou, Jianying, Zhao, Yanqiu, Su, Wu-Chou, Yang, Tsung-Ying, Zhu, Viola W, Millward, Michael, Fan, Yun, Huang, Wen-Tsung, Cheng, Ying, Jiang, Liyan, Brungs, Daniel, Bazhenova, Lyudmila, Lee, Chee Khoon, Gao, Bo, Xu, Yan, Hsu, Wei-Hsun, Zheng, Li, and Janne, Pasi A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Lung Cancer, Clinical Research, Lung, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antibodies, Bispecific, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Exons, Humans, Lung Neoplasms, Mutagenesis, Insertional, Mutation, Protein Kinase Inhibitors, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFRexon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response has not been reached.SignificanceWe report the discovery and early clinical development of sunvozertinib, a potential treatment option for the unmet medical need of EGFRexon20ins NSCLC. This article is highlighted in the In This Issue feature, p. 1599.

Published
2022

4. Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma

Author

Luo, Biyuan, Ma, Fang, Liu, Hao, Hu, Jixiong, Rao, Le, Liu, Chun, Jiang, Yongfang, Kuangzeng, Shuyu, Lin, Xuan, Wang, Chenyang, Lei, Yiyu, Si, Zhongzhou, Chen, Guangshun, Zhou, Ning, Liang, Chengbai, Jiang, Fangqing, Liu, Fenge, Dai, Weidong, Liu, Wei, Gao, Yawen, Li, Zhihong, Li, Xi, Zhou, Guangyu, Li, Bingsi, Zhang, Zhihong, Nian, Weiqi, Luo, Lihua, and Liu, Xianling

Published
2022
Full Text
View/download PDF

9. Discovery and validation of methylation signatures in circulating cell-free DNA for early detection of esophageal cancer: a case-control study

Author

Qiao, Guibin, Zhuang, Weitao, Dong, Bo, Li, Chengcheng, Xu, Jiayue, Wang, Guoqiang, Xie, Liang, Zhou, Zihao, Tian, Dan, Chen, Gang, Tang, Jiming, Zhou, Haiyu, Zhang, Dongkun, Shi, Ruiqing, Chen, Rixin, Nian, Weiqi, Zhang, Yuzi, Zhao, Jing, Wen, Xiaofang, Xu, Yu, Li, Bingsi, Zhang, Zhihong, Cai, Shangli, Ben, Xiaosong, and Qi, Yu

Published
2021
Full Text
View/download PDF

14. Data from Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Author

Wang, Mengzhao, primary, Yang, James Chih-Hsin, primary, Mitchell, Paul L., primary, Fang, Jian, primary, Camidge, D. Ross, primary, Nian, Weiqi, primary, Chiu, Chao-Hua, primary, Zhou, Jianying, primary, Zhao, Yanqiu, primary, Su, Wu-Chou, primary, Yang, Tsung-Ying, primary, Zhu, Viola W., primary, Millward, Michael, primary, Fan, Yun, primary, Huang, Wen-Tsung, primary, Cheng, Ying, primary, Jiang, Liyan, primary, Brungs, Daniel, primary, Bazhenova, Lyudmila, primary, Lee, Chee Khoon, primary, Gao, Bo, primary, Xu, Yan, primary, Hsu, Wei-Hsun, primary, Zheng, Li, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table from Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Author

Wang, Mengzhao, primary, Yang, James Chih-Hsin, primary, Mitchell, Paul L., primary, Fang, Jian, primary, Camidge, D. Ross, primary, Nian, Weiqi, primary, Chiu, Chao-Hua, primary, Zhou, Jianying, primary, Zhao, Yanqiu, primary, Su, Wu-Chou, primary, Yang, Tsung-Ying, primary, Zhu, Viola W., primary, Millward, Michael, primary, Fan, Yun, primary, Huang, Wen-Tsung, primary, Cheng, Ying, primary, Jiang, Liyan, primary, Brungs, Daniel, primary, Bazhenova, Lyudmila, primary, Lee, Chee Khoon, primary, Gao, Bo, primary, Xu, Yan, primary, Hsu, Wei-Hsun, primary, Zheng, Li, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Author

Wang, Mengzhao, primary, Yang, James Chih-Hsin, primary, Mitchell, Paul L., primary, Fang, Jian, primary, Camidge, D. Ross, primary, Nian, Weiqi, primary, Chiu, Chao-Hua, primary, Zhou, Jianying, primary, Zhao, Yanqiu, primary, Su, Wu-Chou, primary, Yang, Tsung-Ying, primary, Zhu, Viola W., primary, Millward, Michael, primary, Fan, Yun, primary, Huang, Wen-Tsung, primary, Cheng, Ying, primary, Jiang, Liyan, primary, Brungs, Daniel, primary, Bazhenova, Lyudmila, primary, Lee, Chee Khoon, primary, Gao, Bo, primary, Xu, Yan, primary, Hsu, Wei-Hsun, primary, Zheng, Li, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure from Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Author

Wang, Mengzhao, primary, Yang, James Chih-Hsin, primary, Mitchell, Paul L., primary, Fang, Jian, primary, Camidge, D. Ross, primary, Nian, Weiqi, primary, Chiu, Chao-Hua, primary, Zhou, Jianying, primary, Zhao, Yanqiu, primary, Su, Wu-Chou, primary, Yang, Tsung-Ying, primary, Zhu, Viola W., primary, Millward, Michael, primary, Fan, Yun, primary, Huang, Wen-Tsung, primary, Cheng, Ying, primary, Jiang, Liyan, primary, Brungs, Daniel, primary, Bazhenova, Lyudmila, primary, Lee, Chee Khoon, primary, Gao, Bo, primary, Xu, Yan, primary, Hsu, Wei-Hsun, primary, Zheng, Li, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

18. Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer.

Author

Zhou, Qing, Zhao, Jun, Chang, Jianhua, Wang, Huijie, Fan, Yun, Wang, Ke, Wu, Gang, Nian, Weiqi, Sun, Yuping, Sun, Meili, Wang, Xiangcai, Shi, Huaqiu, Zheng, Xiangqian, Yao, Sheng, Qin, Mengmeng, Shen, Zhenwei, Yang, Jason, and Wu, Yi‐Long

Subjects
NON-small-cell lung carcinoma, PATIENT safety, ADVERSE health care events, CHINESE people
Abstract

Background: Pralsetinib is a potent, selective RET inhibitor targeting oncogenic RET alterations. As part of the global, phase 1/2 ARROW trial (NCT03037385), the efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion‐positive non–small cell lung cancer (NSCLC) were evaluated. Methods: Adult patients with advanced, RET fusion–positive NSCLC with or without prior platinum‐based chemotherapy were enrolled into two cohorts receiving 400‐mg once‐daily oral pralsetinib. Primary end points were objective response rates assessed by blinded independent central review and safety. Results: Of 68 patients enrolled, 37 had received prior platinum‐based chemotherapy (48.6% with ≥3 prior systemic regimens) and 31 were treatment‐naïve. As of March 4, 2022 (data cutoff), of the patients with measurable lesions at baseline, a confirmed objective response was observed in 22 (66.7%; 95% confidence interval [CI], 48.2–82.0) of 33 pretreated patients, including 1 (3.0%) complete response and 21 (63.6%) partial responses; and in 25 (83.3%; 95% CI, 65.3–94.4) of 30 treatment‐naïve patients, including two (6.7%) complete responses and 23 (76.7%) partial responses. Median progression‐free survival was 11.7 months (95% CI, 8.7–not estimable) in pretreated patients and 12.7 months (95% CI, 8.9–not estimable) in treatment‐naïve patients. The most common grade 3/4 treatment‐related adverse events in 68 patients were anemia (35.3%) and decreased neutrophil count (33.8%). Eight (11.8%) patients discontinued pralsetinib because of treatment‐related adverse events. Conclusion: Pralsetinib showed robust and durable clinical activity with a well‐tolerated safety profile in Chinese patients with RET fusion‐positive NSCLC. Clinical trial registration: NCT03037385. This study assessed efficacy and safety of pralsetinib in Chinese patients with RET fusion‐positive non–small cell lung cancer who had previously received platinum‐based chemotherapy (n = 37) or were treatment‐naïve (n = 31). Pralsetinib has demonstrated a robust, rapid antitumor activity and an overall well‐tolerated safety profile in Chinese patients with RET fusion–positive non–small cell lung cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Blood-based DNA methylation profiling for the detection of ovarian cancer

Author

Li, Ning, primary, Zhu, Xin, additional, Nian, Weiqi, additional, Li, Yifan, additional, Sun, Yangchun, additional, Yuan, Guangwen, additional, Zhang, Zhenjing, additional, Yang, Wenqing, additional, Xu, Jiayue, additional, Lizaso, Analyn, additional, Li, Bingsi, additional, Zhang, Zhihong, additional, Wu, Lingying, additional, and Zhang, Yu, additional

Published
2022
Full Text
View/download PDF

20. Vitamin C-induced competitive binding of HIF-1α and p53 to ubiquitin E3 ligase CBL contributes to anti-breast cancer progression through p53 deacetylation

Author

Xiong, Yan, primary, Xu, Shiyao, additional, Fu, Beibei, additional, Tang, Wanyan, additional, Zaky, Mohamed Y., additional, Tian, Rong, additional, Yao, Rui, additional, Zhang, Shanfu, additional, Zhao, Qingting, additional, Nian, Weiqi, additional, Lin, Xiaoyuan, additional, and Wu, Haibo, additional

Published
2022
Full Text
View/download PDF

23. Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors

Author

Qiu, Miao-Zhen, primary, Zhang, Yang, additional, Guo, Ye, additional, Guo, Wei, additional, Nian, Weiqi, additional, Liao, Wangjun, additional, Xu, Zhongyuan, additional, Zhang, Wenxue, additional, Zhao, Hong-Yun, additional, Wei, Xiaoli, additional, Xue, Liqiong, additional, Tang, Wenbo, additional, Wu, Yunteng, additional, Ren, Guoxin, additional, Wang, Ling, additional, Xi, Jingle, additional, Jin, Yongshuai, additional, Li, Hu, additional, Hu, Chaohong, additional, and Xu, Rui-Hua, additional

Published
2022
Full Text
View/download PDF

24. A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).

Author

Li, Jianyong, primary, Zhou, Keshu, additional, Nian, Weiqi, additional, Cui, Guohui, additional, Wang, Jishi, additional, Zhang, Xiaoping, additional, Cen, Hong, additional, Li, Fei, additional, Yi, Shuhua, additional, Feng, Ru, additional, Xu, Chongyuan, additional, Qian, Wenbin, additional, Liu, Lihong, additional, Li, Caixia, additional, Zhao, Xielan, additional, Chen, Zi, additional, Qiao, Junxiao, additional, Zhang, Hongli, additional, Ahmad, Mohammad, additional, and Zhai, Yifan, additional

Published
2022
Full Text
View/download PDF

25. Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Author

Janne, Pasi A., primary, Wang, Mengzhao, additional, Camidge, D. Ross, additional, Mitchell, Paul, additional, Fang, Jian, additional, Nian, Weiqi, additional, Chiu, Chao-Hua, additional, Zhou, Jianying, additional, Zhao, Yanqiu, additional, Su, Wu-Chou, additional, Yang, Tsung-Ying, additional, Zhu, Viola Weijia, additional, Millward, Michael, additional, Fan, Yun, additional, Huang, Wen-Tsung, additional, Cheng, Ying, additional, Jiang, Liyan, additional, Brungs, Daniel, additional, Zheng, Li, additional, and Yang, James Chih-Hsin, additional

Published
2022
Full Text
View/download PDF

26. Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial

Author

Wang, Ling, primary, Tang, Jiaxi, additional, Chen, Xia, additional, Zhao, Juan, additional, Tang, Wanyan, additional, Liao, Bin, additional, and Nian, Weiqi, additional

Published
2022
Full Text
View/download PDF

27. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

Author

Wang, Mengzhao, Wang, Mengzhao, Yang, James Chih-Hsin, Mitchell, Paul L, Fang, Jian, Camidge, D Ross, Nian, Weiqi, Chiu, Chao-Hua, Zhou, Jianying, Zhao, Yanqiu, Su, Wu-Chou, Yang, Tsung-Ying, Zhu, Viola W, Millward, Michael, Fan, Yun, Huang, Wen-Tsung, Cheng, Ying, Jiang, Liyan, Brungs, Daniel, Bazhenova, Lyudmila, Lee, Chee Khoon, Gao, Bo, Xu, Yan, Hsu, Wei-Hsun, Zheng, Li, Jänne, Pasi A, Wang, Mengzhao, Wang, Mengzhao, Yang, James Chih-Hsin, Mitchell, Paul L, Fang, Jian, Camidge, D Ross, Nian, Weiqi, Chiu, Chao-Hua, Zhou, Jianying, Zhao, Yanqiu, Su, Wu-Chou, Yang, Tsung-Ying, Zhu, Viola W, Millward, Michael, Fan, Yun, Huang, Wen-Tsung, Cheng, Ying, Jiang, Liyan, Brungs, Daniel, Bazhenova, Lyudmila, Lee, Chee Khoon, Gao, Bo, Xu, Yan, Hsu, Wei-Hsun, Zheng, Li, and Jänne, Pasi A

Abstract

Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFRexon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response has not been reached.SignificanceWe report the discovery and early clinical development of sunvozertinib, a potential treatment option for the unmet medical need of EGFRexon20ins NSCLC. This article is highlighted in the In This Issue feature, p. 1599.

Published
2022

29. Additional file 1 of Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma

Author

Luo, Biyuan, Ma, Fang, Liu, Hao, Hu, Jixiong, Rao, Le, Liu, Chun, Jiang, Yongfang, Kuangzeng, Shuyu, Lin, Xuan, Wang, Chenyang, Lei, Yiyu, Si, Zhongzhou, Chen, Guangshun, Zhou, Ning, Liang, Chengbai, Jiang, Fangqing, Liu, Fenge, Dai, Weidong, Liu, Wei, Gao, Yawen, Li, Zhihong, Li, Xi, Zhou, Guangyu, Li, Bingsi, Zhang, Zhihong, Nian, Weiqi, Luo, Lihua, and Liu, Xianling

Abstract

Additional file 1: Table S1. Table S1. 2,321 differentially methylated markers were selected in model construction.

Published
2022
Full Text
View/download PDF

30. Additional file 3 of Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma

Author

Luo, Biyuan, Ma, Fang, Liu, Hao, Hu, Jixiong, Rao, Le, Liu, Chun, Jiang, Yongfang, Kuangzeng, Shuyu, Lin, Xuan, Wang, Chenyang, Lei, Yiyu, Si, Zhongzhou, Chen, Guangshun, Zhou, Ning, Liang, Chengbai, Jiang, Fangqing, Liu, Fenge, Dai, Weidong, Liu, Wei, Gao, Yawen, Li, Zhihong, Li, Xi, Zhou, Guangyu, Li, Bingsi, Zhang, Zhihong, Nian, Weiqi, Luo, Lihua, and Liu, Xianling

Abstract

Additional file 3: Figures S1-S11. Fig. S1 The input DNA amount health, benign, and tumor tissue samples in sequencing analysis. Fig. S2 cfDNA methylation analysis of HCC diagnosis. Fig. S3 GO and KEGG pathway analysis of benign and cancer signals. Fig. S4 Unsupervised hierarchical clustering of tissue-derived 2321 methylation markers selected for HCC diagnosis in the tissue samples and plasma samples. Fig. S5 The specificity and sensitivity of MH model distinguishing tumor from healthy individuals in the training and the validation cohort. Fig. S6 The specificity and sensitivity of BH model distinguishing tumor from healthy individuals in the training and the validation cohort. Fig. S7 The comparison of non-tissue tissue-specific markers and tissue-specific markers in BH model contribution. Fig. S8 The specificity and sensitivity of MB model distinguishing tumor from healthy individuals in the training and the validation cohort. Fig. S9 The ROC of the HCC screening model (malignant score) for HCC diagnosis in the training and the validation cohort. Fig. S10 The correlation of malignant score and benign score with cause of cirrhosis (HCV or non-HCV). Fig. S11 Clinical characteristics of misclassified cirrhotic samples.

Published
2022
Full Text
View/download PDF

31. Additional file 2 of Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma

Author

Luo, Biyuan, Ma, Fang, Liu, Hao, Hu, Jixiong, Rao, Le, Liu, Chun, Jiang, Yongfang, Kuangzeng, Shuyu, Lin, Xuan, Wang, Chenyang, Lei, Yiyu, Si, Zhongzhou, Chen, Guangshun, Zhou, Ning, Liang, Chengbai, Jiang, Fangqing, Liu, Fenge, Dai, Weidong, Liu, Wei, Gao, Yawen, Li, Zhihong, Li, Xi, Zhou, Guangyu, Li, Bingsi, Zhang, Zhihong, Nian, Weiqi, Luo, Lihua, and Liu, Xianling

Abstract

Additional file 2: Table S2. Table S2. Performance of tissue-derived markers in tissue-samples.

Published
2022
Full Text
View/download PDF

36. MiR‐342 controlsMycobacterium tuberculosissusceptibility by modulating inflammation and cell death

Author

Fu, Beibei, primary, Lin, Xiaoyuan, additional, Tan, Shun, additional, Zhang, Rui, additional, Xue, Weiwei, additional, Zhang, Haiwei, additional, Zhang, Shanfu, additional, Zhao, Qingting, additional, Wang, Yu, additional, Feldman, Kelly, additional, Shi, Lei, additional, Zhang, Shaolin, additional, Nian, Weiqi, additional, Chaitanya Pavani, Krishna, additional, Li, Zhifeng, additional, Wang, Xingsheng, additional, and Wu, Haibo, additional

Published
2021
Full Text
View/download PDF

37. Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

Author

Yang, James Chih-Hsin, primary, Wang, Mengzhao, additional, Mitchell, Paul, additional, Fang, Jian, additional, Nian, Weiqi, additional, Chiu, Chao-Hua, additional, Zhou, Jianying, additional, Zhao, Yanqiu, additional, Su, Wu-Chou, additional, Camidge, D. Ross, additional, Yang, Tsung-Ying, additional, Zhu, Viola Weijia, additional, Millward, Michael, additional, Fan, Yun, additional, Huang, Wen Tsung, additional, Cheng, Ying, additional, Jiang, Liyan, additional, Zheng, Li, additional, Ye, Xiuhui, additional, and Janne, Pasi A., additional

Published
2021
Full Text
View/download PDF

39. Progress on Preparation of pH/Temperature-Sensitive Intelligent Hydrogels and Applications in Target Transport and Controlled Release of Drugs

Author

Li, Lixian, He, Yongpeng, Zheng, Xiaodong, Yi, Lin, and Nian, Weiqi

Subjects
Article Subject
Abstract

Hydrogels with three-dimensional network structure, hydrophilic, and insoluble in water which are ideal carrier materials for intelligent drug delivery systems. Intelligent hydrogel has become a research frontier and hotspot because of its intelligence, high efficiency, safety, and convenience in drug controlled and prolonged release. It has a broad application prospect in the medicine and biomedicine fields and can lead the medicine fields into a new era of “precise treatment.” Based on the latest research progress, the main preparation methods of hydrogel and the development of the drug delivery system are briefly introduced. The most promising three intelligent hydrogels in the human physiological environment, namely, pH responsiveness, temperature responsiveness, and pH/temperature dual responsiveness, are emphatically reviewed. Their release mechanisms, targeting transport, and controlled-prolonged release of drug are also discussed. In addition, some suggestions for the main problems and future development were given.

Published
2021
Full Text
View/download PDF

40. Metabolomics-Based Discovery of Molecular Signatures for Triple Negative Breast Cancer in Asian Female Population

Author

Nian Weiqi, Nathaniel Villanueva, Li Lixian, Tao Huan, Zheng Xiaodong, Liu Xingming, and Qi Zhou

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, China, Population, Metabolic network, lcsh:Medicine, Triple Negative Breast Neoplasms, Disease, Article, Mass Spectrometry, 03 medical and health sciences, 0302 clinical medicine, Metabolomics, Breast cancer, Asian People, Internal medicine, medicine, Humans, education, lcsh:Science, Survival rate, Triple-negative breast cancer, Survival analysis, Chromatography, High Pressure Liquid, education.field_of_study, Multidisciplinary, business.industry, lcsh:R, Cancer, Middle Aged, medicine.disease, Survival Analysis, 030104 developmental biology, 030220 oncology & carcinogenesis, lcsh:Q, Female, business
Abstract

Triple negative breast cancer (TNBC) is a devastating cancer disease characterized by its poor prognosis, distinct metastatic patterns, and aggressive biological behavior. Research indicates that the prevalence and presentation of TNBC varies among races, with Asian TNBC patients more commonly presenting with large invasive tumors, high node positivity, and high histologic grade. In this work, we applied ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS)-based metabolomics to discover metabolic signatures in Asian female TNBC patients. Serum samples from 31 TNBC patients and 31 healthy controls (CN) were involved in this study. A total of 2860 metabolic features were detected in the serum samples. Among them, 77 metabolites, whose levels were significantly different between TNBC with CN, were confirmed. Using multivariate statistical analysis, literature mining, metabolic network and pathway analysis, we performed an in-depth study of the metabolic alterations in the Asian TNBC population. In addition, we discovered a panel of metabolic signatures that are highly correlated with the 5-year survival rate of the TNBC patients. This metabolomic study provides a better understanding of the metabolic details of TNBC in the Asian population.

Published
2020

41. Circulating Tumor DNA Methylation Markers for Differential Diagnosis of Hepatocellular Carcinoma

Author

Luo, Biyuan, primary, Ma, Fang, additional, Liu, Hao, additional, Hu, Ji-Xiong, additional, Rao, Le, additional, Liu, Chun, additional, Jiang, Yong-Fang, additional, Kuangzeng, Shu-Yu, additional, Lin, Xuan, additional, Wang, Chenyang, additional, Lei, Yi-Yu, additional, Si, Zhong-Zhou, additional, Chen, Guang-Shun, additional, Zhou, Ning, additional, Liang, Cheng-Bai, additional, Jiang, Fang-Qing, additional, Liu, Feng-E, additional, Dai, Wei-Dong, additional, Liu, Wei, additional, Gao, Ya-Wen, additional, Li, Zhi-Hong, additional, Li, Xi, additional, Li, Bingsi, additional, Zhang, Zhihong, additional, Nian, Weiqi, additional, and Liu, Xianling, additional

Published
2021
Full Text
View/download PDF

42. MicroRNA-325-3p Facilitates Immune Escape of Mycobacterium tuberculosis through Targeting LNX1 via NEK6 Accumulation to Promote Anti-Apoptotic STAT3 Signaling

Author

Fu, Beibei, primary, Xue, Weiwei, additional, Zhang, Haiwei, additional, Zhang, Rui, additional, Feldman, Kelly, additional, Zhao, Qingting, additional, Zhang, Shanfu, additional, Shi, Lei, additional, Pavani, Krishna Chaitanya, additional, Nian, Weiqi, additional, Lin, Xiaoyuan, additional, and Wu, Haibo, additional

Published
2020
Full Text
View/download PDF

44. MiR‐342 controls Mycobacterium tuberculosis susceptibility by modulating inflammation and cell death.

Author

Fu, Beibei, Lin, Xiaoyuan, Tan, Shun, Zhang, Rui, Xue, Weiwei, Zhang, Haiwei, Zhang, Shanfu, Zhao, Qingting, Wang, Yu, Feldman, Kelly, Shi, Lei, Zhang, Shaolin, Nian, Weiqi, Chaitanya Pavani, Krishna, Li, Zhifeng, Wang, Xingsheng, and Wu, Haibo

Abstract

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that places a heavy strain on public health. Host susceptibility to Mtb is modulated by macrophages, which regulate the balance between cell apoptosis and necrosis. However, the role of molecular switches that modulate apoptosis and necrosis during Mtb infection remains unclear. Here, we show that Mtb‐susceptible mice and TB patients have relatively low miR‐342‐3p expression, while mice with miR‐342‐3p overexpression are more resistant to Mtb. We demonstrate that the miR‐342‐3p/SOCS6 axis regulates anti‐Mtb immunity by increasing the production of inflammatory cytokines and chemokines. Most importantly, the miR‐342‐3p/SOCS6 axis participates in the switching between Mtb‐induced apoptosis and necrosis through A20‐mediated K48‐linked ubiquitination and RIPK3 degradation. Our findings reveal several strategies by which the host innate immune system controls intracellular Mtb growth via the miRNA‐mRNA network and pave the way for host‐directed therapies targeting these pathways. Synopsis: The miR‐342/SOCS6 axis promotes anti‐Mtb defense by increasing the production of inflammatory factors, and by switching cell death pathways from necrosis to apoptosis through A20 mediated K48 ubiquitination and degradation of RIPK3. The miR‐342/SOCS6 axis controls susceptibility to Mycobacterium tuberculosis infection in mouse and human.The miR‐342/SOCS6 axis regulates cell death in Mtb‐infected macrophages.Ubiquitination‐dependent degradation of RIPK3 is decisive for the Mtb‐resistance phenotype. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway

Author

Ge Chuang, Fanglin Chen, Haiwei Zhang, Nian Weiqi, Xiaolong Shi, Yongzhong Wu, He Yongpeng, Chao Tang, Lin Yi, and Donglin Wang

Subjects
0301 basic medicine, Akt/PKB signaling pathway, Biophysics, Notch signaling pathway, Cell Biology, Transfection, Cell cycle, Biology, Biochemistry, respiratory tract diseases, Cell biology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Cell culture, 030220 oncology & carcinogenesis, medicine, Erlotinib, Molecular Biology, Protein kinase B, Insulin-like growth factor 1 receptor, medicine.drug
Abstract

Recent evidence supports a role for microRNA-223 (miR-223) in modulating tumor cell sensitivity to chemotherapeutic drugs; however, its role in cellular resistance to the effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) used in treatment of non-small cell lung cancer (NSCLC) remains to be elucidated. The levels of miR-223 in parental cell line (HCC827) and erlotinib resistant HCC827 cell line (HCC827/ER) were detected by qRT-PCR. HCC827/ER cells were treated with MK-2206 to block the Akt signaling pathway or RO4929097 to block the Notch signaling pathway, and then transfected with an miR-223 inhibitor or interference expression plasmid of F-Box/WD repeat-containing protein 7 (FBXW7) or insulin-like growth factor 1 receptor (IGF1R). HCC827 cells were transfected with miR-223 mimics. Next, CCK-8, colony formation, and flow cytometric apoptosis assays were used to assess cell resistance to erlotinib. When compared with its expression in HCC827 cells, miR-223 expression was significantly up-regulated in HCC827/ER cells. Blocking either the Akt or Notch signaling pathway and reducing miR-223 expression resulted in decreased resistance in HCC827/ER cells. Conversely, increasing miR-223 expression induced cell resistance to erlotinib in HCC827 cells. miR-223 enhanced resistance to erlotinib by down-regulating FBXW7 expression. Reducing FBXW7 expression lowered resistance to erlotinib in HCC827/ER cells, while interference with expression of IGF1R produced no significant effect. This study demonstrated that NSCLC cells can up-regulate their levels of miR-223 expression via the Akt and Notch signaling pathways. miR-223 may serve as an important regulator of erlotinib sensitivity in NSCLC cells by targeting FBXW7.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results